$PHVS

Monges Viviane sold $293K of PHVS

Monges Viviane sold 9,667 shares of Pharvaris N.V. (PHVS) at $30.29 ($0.29M total) on 2026-05-21.

Original reporting
SEC EDGAR · Monges Viviane
Published May 26, 2026, 9:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosure may modestly influence short-term sentiment, but it does not provide new information about Pharvaris’ pipeline, finances, or near-term catalysts.

02

Market read

Traders may monitor PHVS for follow-on insider activity, but this filing alone is unlikely to drive a sustained repricing.

03

What to watch

Check for other insiders’ transactions around the same dates and whether the company has concurrent trial/regulatory milestones not mentioned here.

Relevance 6/10Timing: Immediate awareness for sentiment/positioning; not a standalone catalyst.

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

Pharvaris director Monges Viviane sold 9,667 PHVS shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Likely limited/short-lived impact; watch for follow-on insider activity or concurrent news.

Evidence & confidence

This is a routine Form 4 insider transaction with no stated 10b5-1 plan and no accompanying company-specific operational update.

Market effects

Minimal; single-company insider sale without clinical/regulatory updates does not reset sector expectations.

None indicated; filing is company-specific.

None indicated; no cross-border deal/regulatory event mentioned.

Counterpoint

Director sales can be planned for liquidity/tax and may not reflect negative fundamentals, especially absent a clear narrative.

Key entities

  • Pharvaris N.V.

    Subject of the Form 4 insider sale: director Monges Viviane sold 9,667 shares at ~$30.2941/share.

  • Monges Viviane

    Director who executed an open-market sale; holdings reported as 5,500 shares after the transaction.

Related articles

MedAI 8/10

Pharvaris Gains FDA Acceptance For Deucrictibant In Hereditary Angioedema

Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).